EGFR and mTOR as therapeutic targets in glioblastoma

  • The quest for new and improved therapies for glioblastoma (GB) has been mostly unsuccessful in more than a decade despite significant efforts. The few exceptions include the optimization of classical alkylating chemotherapy by including lomustine in the first line regimen for GB with a methylated MGMT promoter and tumor treating fields. The GB signaling network has been well-characterized and genetic alterations resulting in activation of receptor tyrosine kinases and especially epidermal growth factor receptor (EGFR) and downstream mammalian target of rapamycin complex 1 (mTORC1) signaling were found in the majority of GBs. ...

Download full text files

Export metadata

Metadaten
Author:Michael Wilfried RonellenfitschORCiDGND, Anna-Luisa Luger, Joachim Peter SteinbachORCiDGND
URN:urn:nbn:de:hebis:30:3-507611
DOI:https://doi.org/10.18632/oncotarget.27094
ISSN:1949-2553
Pubmed Id:https://pubmed.ncbi.nlm.nih.gov/31413813
Parent Title (English):OncoTarget
Publisher:Impact Journals LLC
Place of publication:[s. l.]
Document Type:Article
Language:English
Year of Completion:2019
Date of first Publication:2019/07/30
Publishing Institution:Universit├Ątsbibliothek Johann Christian Senckenberg
Release Date:2019/08/22
Tag:DDIT4; EGFR; glioblastoma; mTOR; tumor microenvironment
Volume:10
Issue:46
Page Number:3
First Page:4721
Last Page:4723
Note:
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
HeBIS-PPN:453774466
Institutes:Medizin / Medizin
Dewey Decimal Classification:6 Technik, Medizin, angewandte Wissenschaften / 61 Medizin und Gesundheit / 610 Medizin und Gesundheit
Sammlungen:Universit├Ątspublikationen
Licence (German):License LogoCreative Commons - Namensnennung 3.0